DexCom, Inc.
DXCM
$65.49
$0.240.37%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.21B | 1.16B | 1.04B | 1.11B | 994.20M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.21B | 1.16B | 1.04B | 1.11B | 994.20M |
| Cost of Revenue | 477.90M | 468.30M | 447.00M | 457.70M | 400.40M |
| Gross Profit | 731.40M | 688.80M | 589.00M | 655.80M | 593.80M |
| SG&A Expenses | 331.40M | 328.00M | 310.10M | 327.40M | 306.40M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 966.80M | 944.50M | 902.30M | 924.60M | 842.20M |
| Operating Income | 242.50M | 212.60M | 133.70M | 188.90M | 152.00M |
| Income Before Tax | 352.30M | 241.10M | 154.30M | 211.30M | 177.40M |
| Income Tax Expenses | 68.50M | 61.30M | 48.90M | 59.60M | 42.80M |
| Earnings from Continuing Operations | 283.80M | 179.80M | 105.40M | 151.70M | 134.60M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 283.80M | 179.80M | 105.40M | 151.70M | 134.60M |
| EBIT | 242.50M | 212.60M | 133.70M | 188.90M | 152.00M |
| EBITDA | 306.10M | 275.60M | 193.70M | 246.70M | 207.30M |
| EPS Basic | 0.73 | 0.46 | 0.27 | 0.39 | 0.34 |
| Normalized Basic EPS | 0.56 | 0.38 | 0.25 | 0.34 | 0.28 |
| EPS Diluted | 0.70 | 0.45 | 0.27 | 0.38 | 0.34 |
| Normalized Diluted EPS | 0.54 | 0.37 | 0.24 | 0.32 | 0.27 |
| Average Basic Shares Outstanding | 391.10M | 392.10M | 391.10M | 390.60M | 394.20M |
| Average Diluted Shares Outstanding | 407.40M | 408.20M | 407.50M | 406.70M | 410.20M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |